Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons and aggregates of a-synuclein termed Lewy bodies. Fingolimod (FTY720) is an agonist of sphingosine-1 phosphate receptors and an approved oral treatment for multiple sclerosis. Fingolimod elevates brainderived neurotrophic factor (BDNF), an important neurotrophic factor for dopaminergic neurons. BDNF and fingolimod are beneficial in several animal models of PD. In order to validate the therapeutic potential of fingolimod for the treatment of PD, we tested its effect in the subacute MPTP mouse model of PD. MPTP or vehicle was applied i.p. in doses of 30 mg/kg MPTP on five consecutive days. In order to recapitulate the combination of dopamine loss and asynuclein aggregates found in PD, MPTP was first administered in Thy1-A30P-a-synuclein transgenic mice. Fingolimod was administered i.p. at a dose of 0.1 mg/kg every second day. Nigrostriatal degeneration was assayed by stereologically counting the number of dopaminergic neurons in the substantia nigra pars compacta, by analysing the concentration of catecholamines and the density of dopaminergic fibres in the striatum. MPTP administration produced a robust nigrostriatal degeneration, comparable to previous studies. Unexpectedly, we found no difference between mice with and without fingolimod treatment, neither at baseline, nor at 14 or 90 days after MPTP. Also, we found no effect of fingolimod in the subacute MPTP mouse model when we used wildtype mice instead of a-synuclein transgenic mice, and no effect with an increased dose of 1 mg/kg fingolimod administered every day. In order to explain these findings, we analysed BDNF regulation by fingolimod. We did find an increase of BDNF protein after a single injection of fingolimod 0.1 or 1.0 mg/kg, but not after multiple injections, indicating that the BDNF response to fingolimod is unsustainable over time. Taken together we did not observe a neuroprotective effect of fingolimod in the subacute MPTP mouse model of PD. We discuss possible explanations for this discrepancy with previous findings and conclude fingolimod might be beneficial for the nonmotor symptoms of PD.
Pathology in Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), dopamine depletion in the striatum and cytoplasmic a-synuclein inclusions termed Lewy bodies. As a consequence of dopamine deficiency, patients suffer from bradykinesia, rigidity and tremor. The cause of neurodegeneration in PD is unknown and there is currently no causal treatment (Oertel and Schulz 2016; Obeso et al. 2017 ).
The neurotrophin brain-derived neurotrophic factor (BDNF) is involved in growth and differentiation of dopaminergic neurons. Reduction of BDNF expression in rats by antisense oligonucleotide infusion causes death of dopaminergic neurons in the SNc (Porritt et al. 2005) , and mice hypomorphic for the BDNF receptor TrkB show loss of dopaminergic neurons and terminals (Baydyuk et al. 2011) . In PD patients, BDNF expression is reduced in the substantia nigra (Mogi et al. 1999; Parain et al. 1999; Chauhan et al. 2001) as is BDNF in serum and cerebrospinal fluid (Scalzo et al. 2010) . Finally, single-nucleotide polymorphisms in the BDNF gene are associated with the age of onset in familial PD (Karamohamed et al. 2005) . Given this importance of BDNF for the survival of dopaminergic neurons, BDNF administration has been investigated for its potential to protect dopaminergic neurons in PD with promising effects in MPTP-treated monkeys, MPP + -infused rats and 6-hydroxydopamine (6-OHDA)-treated rodents (Frim et al. 1994; Levivier et al. 1995; Shults et al. 1995; Tsukahara et al. 1995; Klein et al. 1999; Pearce et al. 1999) . Subsequently, activation of the BDNF receptor TrkB with small molecule agonists was investigated and found protective in animal models of PD (Nie et al. 2015; Luo et al. 2016) .
Fingolimod (FTY720) -an approved oral drug for relapsing-remitting multiple sclerosis -can cross the blood-brain barrier and increases BDNF in the brain (Deogracias et al. 2012; Di Pardo et al. 2013; Fukumoto et al. 2014; Miguez et al. 2015) . Consequently, fingolimod has been investigated as a treatment option for several neurological diseases (reviewed by O'Sullivan and Dev 2017) .
In this context, we evaluated the effect of fingolimod in the subacute MPTP mouse model of PD. MPTP is given systemically but selectively accumulates in dopaminergic neurons where it inhibits the mitochondrial respiratory chain and leads to apoptotic cell death. In these properties, MPTP toxicity shares several important features with the degeneration of dopaminergic neurons in PD (Jackson-Lewis et al. 2012) . Our findings are unexpected given three studies published during preparation of this manuscript that found beneficial effects of fingolimod in other toxin-based models of PD. Fingolimod protected dopaminergic markers against the toxicity of 6-OHDA, rotenone and an acute regimen of MPTP that causes necrotic death of dopaminergic neurons (Ren et al. 2017; Zhao et al. 2017; Motyl et al. 2018) . In addition, fingolimod reduced a-synuclein pathology in a transgenic mouse model (Vidal-Mart ınez et al., 2016) .
Methods

Animals
The animal experiments were approved by the District Government of North Rhine Westphalia in Recklinghausen, Germany (No 82-02.04.2013.A416) . All mice were housed and handled in a pathogen-free, temperature-controlled facility (20-24°C) with a 12 h light/dark cycle and with food and water ad libitum according to guidelines from the Federation for European Laboratory Animal Science Associations. For all experiments male 12-week-old wildtype (C57BL/6J, IMSR Cat# JAX:000664, RRID: IMSR_JAX:000664) and 12-15 weeks old C57BL6/J-Thy1-A30P-a-synuclein transgenic mice were used. Mice expressing A30P-asynuclein under the Thy1 promoter (kindly provided by Philipp Kahle) are a well-established model for PD (e.g. Rathke-Hartlieb et al. 2001; Krenz et al. 2009 ). These animals were last authenticated in 2017 by staining a-synuclein aggregates and were monitored daily for physical condition and loss of weight.
The number of dopaminergic neurons was the primary endpoint of this study. Our study was based on the assumption that a 20% change in the number of dopaminergic neurons is relevant. This required a sample size of eight animals per group [assuming a mean of 600 tyrosine hydroxylase (TH)-positive neurons per hemisphere, standard deviation 200 neurons, effect size d = 0.6, a = 0.05, Power = 0.2]. In total, 127 animals started into the experiments (see Figs 1b, 2b and 3b). Animals were identified by earmark numbers. They were randomly assigned to the experimental groups by a technical assistant not involved in the analyses. Randomization was carried out using sorting by random numbers. Investigators were blinded for MPTP and fingolimod treatments during sample preparation and analyses using numerical sample identifiers. To minimize animals' suffering during experiments, animals were evaluated daily for weight and for signs of discomfort using a scoring sheet. Animals loosing > 20% of their initial weight or showing substantial signs of discomfort were eliminated from the experiment by cervical dislocation under deep isoflurane anaesthesia. In the three MPTP experiments depicted in Figs 1-3, two animals out of 127 total had to be taken out of the experiment based on these criteria, one in the NaCl group (* in Fig. 1b) and one in the MPTP group (* in Fig. 3b ). Analgetics were not administered.
Subacute MPTP treatment
The subacute MPTP model was executed as described previously (Kowsky et al. 2007; Komnig et al. 2016a,b) . MPTP was dissolved in 0.9% saline and administered i.p. every 24 h over five consecutive days at doses of 30 mg free base per kg of body weight. Controls were injected with 0.9% saline only. Fourteen days or 90 days after the last MPTP injection animals were sacrificed under deep isoflurane anaesthesia by cervical dislocation. The left striata were rapidly dissected on ice, quick-frozen in liquid nitrogen, and stored at À80°C until striatal catecholamine concentrations were measured by HPLC. The right striata and the posterior parts of the same brains were fixed for 24 h in 4% paraformaldehyde and cryoprotected in 30% sucrose for 2 days at 4°C. Brains were frozen by immersion in isopentane (À45°C) and then stored at À80°C for histological analysis.
Fingolimod treatment
On each day of injection, 1 mg fingolimod (Novartis Pharma AG, Basel, Switzerland) was dissolved in 200 lL of 70% (v/v) ethanol and subsequently diluted in 0.9% (w/v) saline to obtain 100 or 10 lg/mL stock solutions. Fingolimod was administered i.p. in doses of 0.1 or 1.0 mg/kg body weight starting 1 day before MPTP treatments, as indicated in Figs 1(a) and 3(a). For the 0.1 mg/kg dose, a 25 g mouse received 250 lL of the 10 lg/mL solution every second day. For the 1.0 mg/kg dose, a 25 g mouse received 250 lL of the 100 lg/mL solution every day. Vehicle controls were injected with equal amounts of 0.9% saline only.
Immunohistochemistry and analysis
The posterior parts of the brains, containing the SN, were serially cut into 30 lm coronal sections and collected free floating. Every third section spanning, the SN was stained for TH as follows. The sections were washed three times in Tris-buffered saline (TBS) with 0.1% TritonX (TBS-T). Endogenous peroxidase was blocked to reduce unspecific background by incubation with 0.3% H 2 O 2 in TBS-T for 30 min. The sections were washed three times using TBS-T. The primary TH antibody (rabbit polyclonal; Merck Millipore, Darmstadt, Germany) was incubated overnight at 4°C in a dilution of 1 : 1000 in TBS-T with 3% (v/v) normal goat serum (Vector Laboratories Cat# S-1000, Burlingame, CA, USA) and has been validated in numerous previous studies. The sections were washed again three times with TBS-T and the secondary antibody (biotinylated goat anti-rabbit IgG; Vector Laboratories Cat# BA-1000, RRID:AB_2313606) was incubated in a dilution of 1 : 200 in TBS-T for 30 min. Subsequently, the sections were washed and incubated with Avidin-Biotin Complex (1 : 100 in TBS-T, Vectastain Elite ABC-Kit; Vector Laboratories Cat# PK-6100) for 30 min, followed by an additional washing step. Antibody binding was visualized via diaminobenzidine (DAB; Sigma Aldrich Cat# 5637, St Louis, MO, USA) in a dilution of 200 lg/mL in phosphatebuffered saline (PBS) for 10 min. Sections were mounted on microscope slides. Nissl counter-staining was performed with cresyl violet (Sigma Aldrich Cat# C5042) and after dehydration sections were coverslipped with Entellan (Merck Millipore Cat# 1.07961).
Tyrosine hydroxylase-positive (dopaminergic) cells in the lateral SNc of the right hemisphere (see supplemental Figure S1a and S1c) were stereologically counted using the optical fractionator method (StereoInvestigator v11; MicroBrightField, Williston, VT, USA) as described (Komnig et al. 2016a,b) . In brief, neurons were manually identified in 50 9 50 lm counting frames presented by the software using an Axio Imager 2 microscope (Carl Zeiss Vision, G€ ottingen, Germany) and an oil immersion 63x objective (NA 1.4). Grid size was 50 9 50 lm, and every third section was analysed. Six slides per brain were analysed, spanning the SNc from bregma levels À3.4 mm to À2.8 mm with the occulomotor nerve crossing the SN and ventral tegmental area at the last slide (Franklin 2001) . In a subset of animals we also counted the number of Nissl-positive, thus neuronal cells in the SNc. Since the DAB staining for TH obscures the Nissl staining, we assumed in this analysis that all TH-positive cells are also Nissl-positive.
For analysis of striatal fibres, the right striata were serially cut into 30 lm coronal sections and three sections spanning the striatum between bregma level +0.26 and +0.98 mm (Franklin 2001) were stained for TH. After washing once with PBS and three times with TBS-T, the primary TH antibody (rabbit polyclonal; Merck Millipore) was incubated overnight at 4°C in a dilution of 1 : 1000 in TBS-T containing 3% normal goat serum (Vector Laboratories). The sections were washed again with TBS-T and secondary (Alexa488-coupled goat anti-rabbit; Invitrogen, Carlsbad, CA, USA) antibody was incubated in a dilution of 1 : 500 in PBS for 1 h. Subsequently, the sections were washed three times with PBS, mounted on glass slides and coverslipped with Fluoromount-G (Southern Biotech, Birmingham, AL, USA).
The density of TH-positive striatal fibres was analysed as previously described (Komnig et al. 2016a,b) . In brief, fluorescence 8-bit images were acquired as z-stack with five slices 1 lm apart using an 60x oil objective (NA 1.35) and an IX81S1F microscope (Olympus, Hamburg, Germany). Prior to image analysis, a maximum intensity projection over z was performed (see supplemental Figures S1b and d). TH-positive fibres were delineated using the auto-threshold function of ImageJ (1.47v; NIH, Bethesda, MD, USA) and subsequently quantified as per cent area using the particle analysis function.
Catecholamine analysis
Catecholamines were measured by HPLC with electrochemical detection as described previously (Komnig et al. 2016a,b) . Frozen tissue of left striata was homogenized in 0.1 M perchloric acid (50 lL/mg tissue wet weight) using ceramic beads and a speed mill (max. pulse for 30 s). Cell debris was pelleted by centrifugation (17 000 g for 20 min at 4°C) and 20 lL of supernatant was injected onto a reverse-phase column (Prontosil 120-3-C18; Thermo Fisher, Waltham, MA, USA). The mobile phase consisted of 85 mM sodium acetate, 35 mM citric acid, 0.5 mM octane sulfonic acid, 0.15 mM EDTA solution and 10% methanol (pH 4.3). Electrochemical detection of dopamine, DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanillic acid) concentration was carried out at 800 mV and a flow rate of 0.8 mL/min. Quantification was performed by comparison with external standards using Chromeleon 6.80 software (Thermo Fisher Scientific). Values are represented as ng catecholamine per mg wet weight tissue. BDNF mRNA quantification Brain-derived neurotrophic factor mRNA was first analysed 2 h after a single injection of fingolimod or vehicle (schematically depicted in Fig. 4a ). Midbrain (Fig. 4b , n = 4 animals per group) or striatum (Fig. 4c , n = 8 animals for vehicle and 0.1 mg/kg, n = 4 animals for 1 mg/kg) were collected on ice after decapitation under deep isoflurane anaesthesia, quick-frozen in liquid nitrogen and stored at À80°C until BDNF gene expression was analysed by quantitative reverse-transcription polymerase chain reaction. Brain-derived neurotrophic factor mRNA was also analysed 8 h after the last of six daily injections of fingolimod 1.0 mg/kg or vehicle, out which the last five were co-administered with 30 mg/kg MPTP as in the subacute MPTP paradigm used in this study (schematically depicted in Fig. 4g ). Midbrain (Fig. 4h) and striatum (Fig. 4i) were collected as above from n = 3 animals per treatment group.
Total RNA was isolated using TRIzol â Reagent (Invitrogen Cat# 15596-026) and stored at À80°C. RNA (500 ng) was reversetranscribed by iScript TM Reverse Transcription Supermix (Bio-Rad Laboratories Cat# 170-8891SP, Munich, Germany) according to the manufacturer's instructions. cDNA was diluted 1 : 12.5 with UltraPure TM DNase/RNase-free distilled water (Invitrogen Cat# 10977049). Three technical replicates were used per primer set for each animal. PCR was carried out using the CFXconnect qrtPCR detection system (Bio-Rad) and hypoxanthine phosphoribosyltransferase 1 (HPRT) as housekeeping control. In each run, external standard curves were generated by dilutions of target genes. PCR cycling conditions were: 10 min denaturation at 95°C, 40 cycles of 15 s denaturation at 95°C, 30 s primer hybridization at 60°C and 30 s annealing at 72°C. As a final step, a melt curve analysis was performed to exclude unspecific gene product amplification. After quantitative reverse-transcription polymerase chain reaction, agarose gel analysis was performed to rule out unspecific products. Relative quantification was calculated by the DDCt-method using the qbase+ software (Biogazelle, Belgium, Gent, Belgium). Data were expressed as relative amount of the target to the amount of HPRT. Values for the control group were set to 1. The following forward (fwd) and reverse (rev) primers were used (5 0 to 3 0 ): HPRT fwd: GCTGGTGAAAAGGACCTCT, HPRT rev: CACAGGACTAGAACACCTGC; BDNF fwd: GACAAGGCAACTTGGCCTAC; BDNF rev: ATTGGGTAGTT CGGCATTGC.
BDNF protein quantification
Brain-derived neurotrophic factor protein was first analysed 2, 4 or 6 days after a single injection of fingolimod or vehicle Vehicle Fingolimod Vehicle Fingolimod (7) (7) (7) (schematically depicted in Fig. 4b ). Animals with vehicle injection were analysed after 2 days. Striatum (Fig. 4e , n = 4 animals) was collected on ice after decapitation under deep isoflurane anaesthesia, quick-frozen in liquid nitrogen and stored at À80°C. BDNF mRNA was also analysed in the same animals used for mRNA (paradigm in Fig. 4f , mRNA in Fig. 4g and h, protein in Fig. 4i and j) .
Frozen tissue was homogenized in PBS (50 lL/mg tissue wet weight) using ceramic beads and a speed mill (max. pulse for 30 s). Cell debris was pelleted by centrifugation (17 000 g for 20 min at 4°C) and supernatants were tested by BDNF sandwich ELISA kit (Cloud-Clone Corp. Cat# SEA011Mu, Houston, TX, USA) according to the manufacturer's instructions.
Quantification of phosphorylated Akt
Striatal tissue was analysed 14 days after the last of five MPTP administrations in a paradigm with MPTP and fingolimod (0.1 mg/ kg) treatment as described in Fig. 2(a) . Sections of the striatum were stained for phospho-Akt (Ser473) (pAkt) as follows. The sections were washed three times in TBS-T. Endogenous peroxidase was blocked to reduce unspecific background by incubation with 3% H 2 O 2 in TBS-T for 30 min. The sections were washed three times using TBS-T. The primary pAkt antibody (Cell Signaling Technology, Inc. Cat# 4060, rabbit monoclonal, Danvers, MA, USA) was incubated overnight at 4°C in a dilution of 1 : 100 in TBS-T with 5% normal goat serum (Vector Laboratories). The sections were washed again three times with TBS-T and the secondary antibody (biotinylated goat anti-rabbit IgG; Vector Laboratories) was incubated in a dilution of 1 : 200 in TBS-T for 30 min. Subsequently, the sections were washed and incubated with avidin-biotin complex (Vector Laboratories) 1 : 100 in TBS-T for 30 min, followed by an additional washing step. Antibody binding was visualized via DAB (Sigma Aldrich) in a dilution of 200 lg/mL in PBS for 10 min. After dehydration sections were coverslipped with Entellan (Merck Millipore). For each animal, three random images spanning the striatum (bregma level +0.98 mm, Franklin 2001) were acquired using an 10x objective and a BX51 microscope (Olympus). DABpositive cells were counted manually using the Cell Counter plugin for ImageJ (NIH). n = 3 animals were analysed per group and for each animal the median value from the three images was included in the analysis.
Statistical analyses
The study was not pre-registered. Data are presented as mean AE SEM with 'n' equal to the number of animals, and with a marker for each animal. Power analysis was carried out with G*Power. All other statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Results in Figs 1-3 were analysed by two-way ANOVA with factors fingolimod (yes/no) and MPTP (yes/no) followed by Bonferroni post hoc tests. The analysis of Fig. 4 is described in the text. The null hypothesis was rejected at the 0.05 level. In graphs, p values are depicted as *p < 0.05.
Results
Effect of fingolimod (0.1 mg/kg) in a-synuclein transgenic mice Parkinson's disease is characterized by the degeneration of dopaminergic neurons and a-synuclein aggregates. In order to test fingolimod in a PD model combining these two pathogenic principles, we administered MPTP in age-matched A30P-a-synuclein transgenic (A30P tg) mice (Rathke-Hartlieb et al. 2001; Szego et al. 2012) . In addition, animals were either injected with 0.1 mg/kg fingolimod or vehicle (Fig. 1a) . This dosing regimen (0.1 mg/kg every second day) increases BDNF mRNA and protein (Deogracias et al. 2012; Di Pardo et al. 2013 ). In mice not treated with MPTP we found no difference in the number of dopaminergic neurons in the SNc as identified by staining for TH between animals treated with fingolimod versus vehicle (Fig. 1c) . There was no difference between animals treated with fingolimod for 20 days (but not MPTP) and animals with vehicle only, and there was no difference between animals treated with fingolimod for 96 days (but not MPTP) and animals treated with vehicle only. Similarly, there was no difference in the number of Nissl-positive cells in the SNc (Fig. 1d) , the area occupied by dopaminergic fibres in the dorsal (Fig. 1e ) or ventral striatum (Fig. 1f) , or in the concentration of striatal catecholamines ( Fig. 1g and h ). Taken together, systemic administration of 0.1 mg/kg fingolimod every second day had no impact on the dopaminergic system of adult A30P tg mice.
Mice treated with MPTP (30 mg/kg i.p. on five consecutive days) were analysed 14 days after the last MPTP injection, the time point when degeneration was completed in previous studies (Kowsky et al. 2007; Komnig et al. 2016b) . MPTP administration resulted in a robust decline in the number of SNc dopaminergic neurons (45%, Fig. 1c) , similar to previous studies using the same paradigm (Komnig et al. 2016b ). There was no difference between mice treated with fingolimod and mice treated with vehicle (Fig. 1c) . In a subset of animals, we also quantified the number of Nisslpositive cells in the SNc in order to demonstrate that the decline in TH-positive neurons results from cell death and not merely from down-regulation of TH. Nissl-positive cells in the SNc (Fig. 1d) and also striatal markers (Fig. 1e-h ) declined with MPTP in an extent similar to previous studies, but animals treated with fingolimod did not differ from animals without fingolimod.
Between 14 and 90 days after MPTP administration, new dopaminergic terminals sprout from remaining axons in the striatum, leading to a partial restoration of dopaminergic fibres in the striatum (Fig. 1e and f) and striatal catecholamines ( Fig. 1g and h ). The extent of this sprouting was statistically significant (two-way ANOVA) and similar to previous studies (Kowsky 2007; Komnig et al. 2016b ), but fingolimod treatment did not affect the extent of sprouting.
Effect of fingolimod (0.1 mg/kg) in wild-type mice The lacking effect of fingolimod in A30P-a-synuclein transgenic mice subjected to subacute MPTP contrasts with the effects of fingolimod in mouse models of PD based on 6-OHDA and rotenone (Ren et al. 2016; Zhao et al. 2017) . In order to rule out that our negative finding results from the use of A30P-a-synuclein transgenic mice, we tested the effect of fingolimod in C57BL6/J wild-type mice using the same MPTP and fingolimod dosing (Fig. 2a) . Fingolimod did not alter nigrostriatal markers in wild-type mice not treated with MPTP ( Fig. 2c-h ). MPTP robustly decreased nigrostriatal markers, but fingolimod did not alter the number of TH-positive neurons in the SNc analysed 14 days after the last MPTP injection (Fig. 2c) , the number of Nissl-positive cells in the SNc, (Fig. 2d) , the density of TH-positive fibres in the striatum (Fig. 2e and f) or striatal catecholamines ( Fig. 2g and h ).
Effect of high dose fingolimod (1.0 mg/kg) in wildtype mice The dosing of fingolimod varies among published studies, and some studies used a higher dose (Fukumoto et al. 2014; Miguez et al. 2015) . In order to rule out that our negative findings resulted from too little fingolimod, we used daily administration of a high-dose fingolimod (1.0 mg/kg body weight) in wild-type mice (Fig. 3a) . Even at the high dosage here was neither an effect of fingolimod in mice not treated with MPTP nor in mice treated with MPTP ( Fig. 3c-h ). There was no difference between mice treated with fingolimod or vehicle in the number of dopaminergic neurons in the SNc (Fig. 3c) , the number of Nissl-positive cells (Fig. 3d) , fibre density in the striatum (Fig. 3e and f) , or striatal catecholamines (Fig. 3g and h) .
BDNF induction by fingolimod
The lacking neuroprotective effect of fingolimod was unexpected. We therefore revisited BDNF induction by fingolimod. First, we analysed BDNF mRNA by quantitative PCR 2 h after a single injection of fingolimod (Fig. 4a-c) . In midbrain samples, we observed a small increase in response to 0.1 mg/kg fingolimod (Fig. 4b ), but the difference to the control condition was not statistically significant (one-way ANOVA). In striatal samples (Fig. 4c) , there was a significant increase with the higher dose of 1.0 mg/kg, but not with the lower dose (one-way ANOVA and Holm-Sidak's multiple comparisons test). We then analysed BDNF protein by ELISA (Fig. 4d) . In striatal samples (Fig. 4e) , there was a significant increase of BDNF protein 2 days after injection of 0.1 mg/kg fingolimnod (t-test). Subsequently, we analysed BDNF in a paradigm as used for the subacute MPTP model (Fig. 4f ). With these repeated injections of 1.0 mg/kg fingolimod, there was no increase in BDNF mRNA at the time point of analysis in either midbrain (Fig. 4g) or striatum ( Fig. 4h ) (one-way ANOVA). For BDNF protein ( Fig. 4i and  j) , there was also no significant difference (one-way ANOVA).
In order to determine whether fingolimod retains any effect after mutliple injections, we measured phosphorylation of Akt, which is considered downstream of sphingosine-1 phosphate receptor (S1PR) activation and upstream of BDNF mRNA regulation (Deogracias et al. 2012; Ren et al. 2016) . In slices from animals treated with Fingolimod (0.1 mg/kg) for 6 days and analysed 14 days after the last injection as described in Fig. 2(a) , the number of pAkt-positive cells in the striatum was significantly larger with fingolimod treatment than in the vehicle group (Fig. 4k , quantified in Fig. 4l, t-test) .
Discussion
In this study we found no effect of fingolimod, applied in two different dosing regimens, in the subacute MPTP mouse model of PD using wild-type mice or A30P-a-synuclein transgenic mice. These findings were unexpected given previous findings by others demonstrating (i) BDNF induction by fingolimod, (ii) neuroprotective effects of BDNF in MPTP-based models and (iii) neuroprotective effects of fingolimod in other PD models.
The extent of nigrostriatal degeneration induced by MPTP in this study was similar to our previous studies (Kowsky et al. 2007; Komnig et al. 2016b) , supporting that the subacute MPTP model was successfully established. Combining all three populations used in this study we can conclude with reasonable error probabilities (a < 0.05, b < 0.2) that the effect of fingolimod on TH-positive neurons is below 10% (effect size d < 0.3).
The extent of BDNF increase we observed following a single application of fingolimod (Fig. 4a-f ) was similar as compared with earlier studies with 0.1 mg/kg (Deogracias et al. 2012; Di Pardo et al. 2013) , 0.3 mg/kg (Miguez et al. 2015) or 1.0 mg/kg (Fukumoto et al. 2014) . In contrast, we did not observe an increase in BDNF after repeated applications (Fig. 4f-j) . Fingolimod is an agonist of the S1PR, a G-protein coupled receptor. G-protein coupled receptors are known to desensitize in response to prolonged or repeated activation. Yet, the increased number of pAkt positive cells 14 days after six injections of fingolimod ( Fig. 4k and l) indicates that the desensitization of the fingolimod effect unlikely occurs already at the level of the S1PR receptor. In apparent contrast to our findings, repeated administration of fingolimod was successfully used in a mouse model of Rett syndrome, a neurodevelopmental disorder characterized by low amounts of BDNF (Deogracias et al. 2012) . It is possible that desensitization of the fingolimod effect upon repeated administration is less pronounced in mice with constitutively low BDNF, when given during development, or when fingolimod is only given every 4 days as performed by Deogracias et al. However, it should be noted that to our knowledge previous studies have not quantified BDNF amounts in the brain after repeated administration. Based on these findings we hypothesize that fingolimod did not protect dopaminergic neurons in the subacute MPTP model because it did not lead to a sustained increase in BDNF. At least, the increase in BDNF was not as pronounced as the increase achieved by previous manipulations applied in the MPTP model, which include administration of recombinant protein (Tsukahara et al. 1995; Pearce et al. 1999 ) and implantation of BDNF-producing cells (Frim et al. 1994) .
Fingolimod is an anti-inflammatory agent with diverse effects (O'Sullivan and Dev 2017), including regulation of histone deacetylases (Hait et al. 2014; Segura-Ulate et al. 2017) . So BDNF increase is not the only pathway by which fingolimod can be neuroprotective. Fingolimod shows beneficial effects against the toxicity of rotenone, 6-OHDA and an acute regimen of MPTP (Ren et al. 2013; Zhao et al. 2017; Motyl et al. 2018) . The fingolimod effect against 6-OHDA is blocked by W146, a sphingosine-1-phosphatereceptor antagonist (Zhao et al. 2017) , but none of the cited studies demonstrated that the fingolimod effects is mediated by a BDNF increase. Only the functional effect of fingolimod on gut mobility in a a-synuclein-based transgenic mouse model was shown to be blocked by the TrkB receptor antagonist ANA-12 (Vidal et al., 2016) , but this is an entirely different context.
So why did fingolimod protect dopaminergic neurons against rotenone, 6-OHDA and an acute regimen of MPTP (Ren et al. 2013; Zhao et al. 2017; Motyl et al. 2018) , but not against subacute MPTP (this study)? First, cell death mechanisms differ between PD models (Meredith and Rademacher 2011) . Cell death in the subacute MPTP mouse model is mainly apoptotic, similar to PD patients (Tatton and Kish 1997; Jackson-Lewis et al. 2012) . Cell death in the acute MPTP model (Motyl et al., used 40 mg/kg in 1 day) is by necrosis (Jackson-Lewis et al., 1995) . Rotenone also impairs mitochondrial complex I as does MPTP, but its effect is not limited to dopaminergic neurons (Dauer and Przedborski 2003) . Interestingly, fingolimod has been hypothesized to act primarily on astrocytes rather than neurons (Choi et al. 2011; Colombo et al. 2014 ). In the 6-OHDA model, cell death is not caused by mitochondrial impairment but by direct generation of reactive oxygen species (Blum et al. 2001; Dauer and Przedborski 2003) . It is plausible that these differences in cell death mechanisms explain the different effects of fingolimod. Of note, fingolimod did not inhibit apoptosis in a mouse model of traumatic brain injury (Mencl et al. 2014) , consistent with our finding that fingolimod did not block apoptosis in the subacute MPTP model.
Furthermore, there were differences in readout parameters between our and the cited studies. Motyl et al. did not quantify the number of dopaminergic neurons in the substantia nigra but only analysed TH immunoreactivity in the striatum. TH activity is known to be down-regulated by MPTP, in particular with the acute MPTP regimen Motyl et al. used (Xu et al. 2005; Meredith and Rademacher 2011) . TH measurements are therefore not a reliable measurement for the integrity of dopaminergic neurons. For this reason, we and others count in the SNc not only the number of THpositive neurons but also the number of Nissl-positive neurons. Ren et al. and Zhao et al. counted TH-positive neurons in the SNc but not Nissl-positive neurons. For the analysis of dopaminergic axon terminals in the striatum, we and others have replaced since 2007 the analysis of TH immunoreactivity on low magnification images by the quantification of the density of TH-positive fibres in highmagnification images because it produces better quality data (Kowsky et al. 2007 In summary, fingolimod protects dopaminergic neurons against 6-OHDA and rotenone (Ren et al. 2013; Zhao et al. 2017) , and possibly against an acute regimen of MPTP (Motyl et al. 2018) , but not against subacute MPTP toxicity (this study). Differences in cell death mechanisms likely account for this discrepancy, and the protective mechanism likely involves other pathways than BDNF increase.
Given these findings, should fingolimod be pursued as a therapeutic strategy in PD? Since fingolimod did not protect against the apoptotic degeneration of dopaminergic neurons resulting from mitochondrial impairment (this study), fingolimod is unlikely to reduce the degeneration of dopaminergic neurons in PD that occurs by a similar mechanism (e.g. Jackson- Lewis et al. 2012) . However, PD patients suffer from a number of non-motor symptoms that do not respond to dopaminergic medication and are not caused by degeneration of dopaminergic neurons. These symptoms include memory and gastrointestinal problems and are likely caused by protein aggregates (Yoritaka et al. 2013; Falkenburger et al. 2016 and references therein). Fingolimod improves memory (Miguez et al. 2015) and reduces brain atrophy (Di Pardo et al. 2013 ) in mouse models of Huntington disease. Moreover, oral fingolimod (0.5 mg/kg twice weekly for 15 months) decreases the intestinal synucleinopathy observed in A53T-a-synuclein transgenic mice and improves gut motility (Vidal-Mart ınez et al. 2016) . Fingolimod also ameliorates amyloid beta induced motor behaviour in a mouse model of Alzheimer disease (Fukumoto et al. 2014) . Finally, fingolimod is generally well tolerated. In the absence of other pathologies, fingolimod did not alter the dopaminergic system in mice (his study), impair object recognition (Fukumoto et al. 2014) , gut motility (Vidal-Mart ınez et al. 2016) or neurological severity score (Mencl et al. 2014) . Also in multiple sclerosis patients fingolimod shows a good safety profile (e.g. Calabresi et al. 2014) . These findings indicate that fingolimod might be beneficial for non-motor symptoms of PD symptoms, which are a primary therapeutic challenge in PD (Reichmann 2015) . 
